Downregulation of SAFB Sustains the NF-κB Pathway by Targeting TAK1 during the Progression of Colorectal Cancer

被引:35
|
作者
Jiao, Hong-Li [1 ,2 ,3 ]
Ye, Ya-Ping [1 ,2 ,3 ]
Yang, Run-Wei [1 ,2 ,3 ]
Sun, Hui-Ying [1 ,2 ,3 ]
Wang, Shu-Yang [1 ,2 ,3 ]
Wang, Yong-Xia [1 ,2 ,3 ]
Xiao, Zhi-Yuan [1 ,2 ,3 ]
He, Liu-Qing [1 ,2 ,3 ]
Cai, Juan-Juan [1 ,2 ,3 ]
Wei, Wen-Ting [1 ,2 ,3 ]
Chen, Yan-Ru [1 ,2 ,3 ]
Gu, Chun-Cai [1 ,2 ,3 ]
Cai, Yue-Long [1 ,2 ,3 ]
Hu, Yun-Teng [1 ,2 ,3 ]
Lai, Qiu-Hua [1 ,2 ,3 ]
Qiu, Jun-Feng [1 ,2 ,3 ]
Liang, Li [1 ,2 ,3 ]
Cao, Guang-Wen [4 ]
Liao, Wen-Ting [1 ,2 ,3 ]
Ding, Yan-Qing [1 ,2 ,3 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China
[2] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Guangdong, Peoples R China
[3] Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou, Guangdong, Peoples R China
[4] Second Mil Med Univ, Dept Epidemiol, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
SIGNALING PATHWAYS; TNF-ALPHA; ACTIVATION; KINASE; PROTEIN; STRESS; TAB1; PHOSPHORYLATION; TRANSCRIPTION; METASTASIS;
D O I
10.1158/1078-0432.CCR-17-0747
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To investigate the role and the underlying mechanism of scaffold attachment factor B (SAFB) in the progression of colorectal cancer (CRC). Experimental Design: SAFB expression was analyzed in the Cancer Outlier Profile Analysis of Oncomine and in 175 paraffin-embedded archived CRC tissues. Gene Ontology analyses were performed to explore the mechanism of SAFB in CRC progression. Western blot, RT-PCR, luciferase assay, and chromatin immuno-precipitation (ChIP) were used to detect the regulation of transforming growth factor-b-activated kinase 1 (TAK1) and NF-kappa B signaling by SAFB. The role of SAFB in invasion, metastasis, and angiogenesis was investigated using in vitro and in vivo assays. The relationship between SAFB and TAK1 was analyzed in CRC tissues. Results: SAFB was downregulated in CRC tissues, and low expression of SAFB was significantly associated with an aggressive phenotype and poorer survival of CRC patients. The downregulation of SAFB activated NF-kappa B signaling by targeting the TAK1 promoter. Ectopic expression of SAFB inhibited the development of aggressive features and metastasis of CRC cells both in vitro and in vivo. The overexpression of TAK1 could rescue the aggressive features in SAFB-overexpressed cells. Furthermore, the expression of SAFB in CRC tissues was negatively correlated with the expression of TAK1-and NF-kappa B-related genes. Conclusions: Our results show that SAFB regulated the activity of NF-kappa B signaling in CRC by targeting TAK1. This novel mechanism provides a comprehensive understanding of both SAFB and the NF-kappa B signaling pathway in the progression of CRC and indicates that the SAFB-TAK1-NF-kappa B axis is a potential target for early therapeutic intervention in CRC progression. (C) 2017 AACR.
引用
收藏
页码:7108 / 7118
页数:11
相关论文
共 50 条
  • [1] Natural cyclopeptide RA-V inhibits the NF-κB signaling pathway by targeting TAK1
    Zhe Wang
    Simeng Zhao
    Lihua Song
    Yuzhi Pu
    Qiang Wang
    Guangzhi Zeng
    Xing Liu
    Ming Bai
    Shao Li
    Fabao Gao
    Lijuan Chen
    Chen Wang
    Ninghua Tan
    Cell Death & Disease, 9
  • [2] Natural cyclopeptide RA-V inhibits the NF-κB signaling pathway by targeting TAK1
    Wang, Zhe
    Zhao, Simeng
    Song, Lihua
    Pu, Yuzhi
    Wang, Qiang
    Zeng, Guangzhi
    Liu, Xing
    Bai, Ming
    Li, Shao
    Gao, Fabao
    Chen, Lijuan
    Wang, Chen
    Tan, Ninghua
    CELL DEATH & DISEASE, 2018, 9
  • [3] MiR-143 Targeting TAK1 Attenuates Pancreatic Ductal Adenocarcinoma Progression via MAPK and NF-κB Pathway In Vitro
    Huang, Feng-Ting
    Peng, Juan-Fei
    Cheng, Wen-Jie
    Zhuang, Yan-Yan
    Wang, Ling-Yun
    Li, Chu-Qiang
    Tang, Jian
    Chen, Wen-Ying
    Li, Yuan-Hua
    Zhang, Shi-Neng
    DIGESTIVE DISEASES AND SCIENCES, 2017, 62 (04) : 944 - 957
  • [4] MiR-143 Targeting TAK1 Attenuates Pancreatic Ductal Adenocarcinoma Progression via MAPK and NF-κB Pathway In Vitro
    Feng-Ting Huang
    Juan-Fei Peng
    Wen-Jie Cheng
    Yan-Yan Zhuang
    Ling-Yun Wang
    Chu-Qiang Li
    Jian Tang
    Wen-Ying Chen
    Yuan-Hua Li
    Shi-Neng Zhang
    Digestive Diseases and Sciences, 2017, 62 : 944 - 957
  • [5] TAK1 Suppresses a NEMO-Dependent but NF-κB-Independent Pathway to Liver Cancer
    Bettermann, Kira
    Vucur, Mihael
    Haybaeck, Johannes
    Koppe, Christiane
    Janssen, Joern
    Heymann, Felix
    Weber, Achim
    Weiskirchen, Ralf
    Liedtke, Christian
    Gassler, Nikolaus
    Mueller, Michael
    de Vos, Rita
    Wolf, Monika Julia
    Boege, Yannick
    Seleznik, Gitta Maria
    Zeller, Nicolas
    Erny, Daniel
    Fuchs, Thomas
    Zoller, Stefan
    Cairo, Stefano
    Buendia, Marie-Annick
    Prinz, Marco
    Akira, Shizuo
    Tacke, Frank
    Heikenwalder, Mathias
    Trautwein, Christian
    Luedde, Tom
    CANCER CELL, 2010, 17 (05) : 481 - 496
  • [6] TAK1 is critical for IκB kinase-mediated activation of the NF-κB pathway
    Takaesu, G
    Surabhi, RM
    Park, KJ
    Ninomiya-Tsuji, J
    Matsumoto, K
    Gaynor, RB
    JOURNAL OF MOLECULAR BIOLOGY, 2003, 326 (01) : 105 - 115
  • [7] Lactate dehydrogenase A promotes nasopharyngeal carcinoma progression through the TAK1/NF-κB Axis
    Li, Yingzi
    Chen, Lanfang
    Zheng, Qiaochong
    Liu, Guanxin
    Wang, Mengjiao
    Wei, Shupei
    Chen, Tao
    MOLECULAR BIOLOGY REPORTS, 2024, 51 (01)
  • [8] Cinobufacini retards progression of pancreatic ductal adenocarcinoma through targeting YEATS2/TAK1/NF-κB axis
    Lan, Tian
    Chen, Hang-fei
    Zheng, Fang
    Huang, Hui
    Wu, Qi
    Fan, Xue-yu
    Wang, Si-wei
    Zhang, Feng
    PHYTOMEDICINE, 2023, 109
  • [9] A Novel Biological Role of α-Mangostin via TAK1–NF-κB Pathway against Inflammatory
    Wenshu Zou
    Peng Yin
    Yaran Shi
    Na Jin
    Qian Gao
    Jiandong Li
    Fenghua Liu
    Inflammation, 2019, 42 : 103 - 112
  • [10] Targeting NF-κB for colorectal cancer
    Sakamoto, Kei
    Maeda, Shin
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2010, 14 (06) : 593 - 601